COVID-19 therapies for mild to moderately ill patients

COVID-19 therapies for mild to moderately ill patients

By British Columbia COVID-19 Therapeutics Committee/ David Patrick, MD, FRCPC, MHSc

Recently, two novel agents have become available in BC for the treatment of COVID-19 in mild to moderately ill patients: a direct-acting oral antiviral, nirmatrelvir/ritonavir, and an IV antiviral, remdesivir. A monoclonal antibody, sotrovimab, was also in widespread use until recently; however, its utility has been limited due to loss of activity against the BA.2 variant of Omicron.